Your browser doesn't support javascript.
loading
Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities.
Al-Dury, Samer; Kanberg, Nelly.
Afiliação
  • Al-Dury S; Department of Medicine, Gastroenterology and Hepatology Unit, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
  • Kanberg N; Institution of Medicine, University of Gothenburg, 405 30 Gothenburg, Sweden.
Vaccines (Basel) ; 12(2)2024 Feb 15.
Article em En | MEDLINE | ID: mdl-38400180
ABSTRACT
This review addresses the vital role of vaccinations in managing patients with chronic liver disease (CLD), especially in the context of the post-COVID-19 landscape. The pandemic has highlighted the unique vulnerabilities of CLD patients, including those awaiting liver transplantation and post-transplant individuals, who face heightened risks of infection due to compromised immune responses. Recent advancements in vaccine technology, such as mRNA platforms, novel adjuvants, and advanced delivery systems, have significantly accelerated vaccine development, enhancing both speed and efficacy. Moreover, the emergence of personalized vaccines, tailored to everyone's unique immunological profile, presents new opportunities, particularly for those with chronic conditions. This review synthesizes the current state of evidence regarding vaccine recommendations for CLD patients, focusing on their response to vaccinations and proposing effective strategies to protect this vulnerable group from vaccine-preventable diseases. It also explores the challenges in implementing these strategies and considers the impact of emerging vaccine delivery systems on improving outcomes for CLD patients. The paper aims to provide nuanced guidance on vaccination in the rapidly evolving healthcare landscape, addressing both technological innovations and comprehensive patient care strategies.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia